Results of Phase III Bravo Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
. - Primary endpoint of reducing annualized relapse rate was not statistically achieved - Following a standard adjustm…
. - Primary endpoint of reducing annualized relapse rate was not statistically achieved - Following a standard adjustm…
. - Phase III ALLEGRO study met primary endpoint and key secondary endpoints: - 23 percent reduction in annualized r…
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that dat…
. - Positive benefit-risk profile of laquinimod sustained in Phase II extension study - 52 percent reduction (p=0.0006…
. - Enhanced levels of brain derived neurotrophic factor, possibly contributing to neuroprotection, were shown in laqui…
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that the…
Teva Pharmaceutical Industries Ltd.(NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced completio…